Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Personalized serum proteome profiles of COVID-19-associated acute respiratory distress syndrome in response to mesenchymal stem cell therapy

ABSTRACT: Five COVID-19-related ARDS patients who consented to compassionate placenta-derived (pc)-MSC treatment were followed for clinical response and disease progression. Serum samples were collected before and after pc-MSC infusion for quantitative proteomics analysis.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Denise Utami Putri

PROVIDER: PXD043740 | JPOST Repository | Thu Jul 13 00:00:00 BST 2023

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20211216_3835_TMUCLHan_TMT10B03E1_01.raw	Raw
	20211216_3836_TMUCLHan_TMT10B03E1_02.raw	Raw
	20211216_3837_TMUCLHan_TMT10B03E2_01.raw	Raw
	20211216_3838_TMUCLHan_TMT10B03E2_02.raw	Raw
	20211216_3839_TMUCLHan_TMT10B03E3_01.raw	Raw

Items per page:

1 - 5 of 17

Similar Datasets

Plasma proteomics-based biomarkers for predicting response to mesenchymal stem cell therapy in severe COVID-19

Project description:In March 2020, we performed a multicenter, randomized, double-blind phase II study of mesenchymal stem cells (MSCs) therapy in patients with severe COVID-19 (ClinicalTrials.gov: NCT04288102). Findings showed that MSC was a potentially effective therapeutic approach for patients with severe COVID-19, but not all patients responded well. To further understand the proteomic biomarkers of response to MSC therapy in patients with severe COVID-19, we characterize the proteomic profile of 58 patient pre-MSC treatment plasma samples (35 responders versus 23 non-responders) by using proteomics assays. The project aims to identify potential biomarkers for predicting response to MSC therapy by pre-MSC treatment plasma proteomic profile in severe COVID-19.

2023-05-10 | PXD042106 |

Severe acute respiratory syndrome coronavirus 2

Project description:Coagulation Profile and COVID-19

| PRJDB17509 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:COVID-19 whole genome sequencing data

| PRJNA1056846 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Wastewater Surveillance for COVID-19 (AquaVitas/NWSS)

| PRJNA771693 | ENA

Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome.

Project description:Acute respiratory distress syndrome (ARDS) is a devastating hypoxemic respiratory failure, characterized by disruption of the alveolar-capillary membrane barrier. Current management for ARDS remains supportive, including lung-protective ventilation and a conservative fluid strategy. Mesenchymal stem cells (MSCs) have emerged as a potentially attractive candidate for the management of ARDS through facilitating lung tissue regeneration and repair by releasing paracrine soluble factors. Over the last decade, a variety of strategies have emerged to optimize MSC-based therapy. Among these, the strategy using genetically modified MSCs has received increased attention recently due to its distinct advantage, in conferring incremental migratory capacity and, enhancing the anti-inflammatory, immunomodulatory, angiogenic, and antifibrotic effects of these cells in numerous preclinical ARDS models, which may in turn provide additional benefits in the management of ARDS. Here, we provide an overview of recent studies testing the efficacy of genetically modified MSCs using preclinical models of ARDS.

| S-EPMC6915956 | biostudies-literature

Transcriptomic profile of human mesenchymal stem cells after statins treatment

Project description:Analysis of the effect of all available statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, pravastatin, rosuvastatin, and pitavastatin) on the expression of genes in human cell cultures to investigate potential anti-inflammatory effect during COVID-19 disease. Transcription profiling was done using microarray assay.

2024-01-01 | E-MTAB-11579 | biostudies-arrayexpress

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

Severe acute respiratory syndrome coronavirus 2

Project description:Whole-genome sequencing of COVID-19 clinical isolates

| PRJNA623586 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Animal model study for COVID-19 using Syrian hamsters

| PRJDB14262 | ENA

Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2

Project description:We studied the host transcriptional response to SARS-CoV-2 by performing metagenomic sequencing of upper airway samples in 234 patients with COVID-19 (n=93), other viral (n=100) or non-viral (n=41) acute respiratory illnesses (ARIs). Compared to other viral ARIs, COVID-19 was characterized by a diminished innate immune response, with reduced expression of genes involved in toll-like receptor and interleukin signaling, chemokine binding, neutrophil degranulation and interactions with lymphoid cells. Patients with COVID-19 also exhibited significantly reduced proportions of neutrophils, macrophages, and increased proportions of goblet, dendritic and B-cells, compared to other viral ARIs. Using machine learning, we built 27-, 10- and 3-gene classifiers that differentiated COVID-19 from other acute respiratory illnesses with AUCs of 0.981, 0.954 and 0.885, respectively. Classifier performance was stable at low viral loads, suggesting utility in settings where direct detection of viral nucleic acid may be unsuccessful. Taken together, our results illuminate unique aspects of the host transcriptional response to SARS-CoV-2 in comparison to other respiratory viruses and demonstrate the feasibility of COVID-19 diagnostics based on patient gene expression.

2020-08-12 | GSE156063 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data